[Federal Register Volume 76, Number 40 (Tuesday, March 1, 2011)]
[Notices]
[Pages 11212-11213]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-4436]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and 
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) 
the Department of Defense announces the following Federal Advisory 
Committee Meeting of the Uniform Formulary Beneficiary Advisory Panel 
(hereafter referred to as the Panel).

DATES: March 24, 2011, from 9 a.m.- 1 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Stacia Spridgen, 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel, 4130 Stanley Road, Suite 208, Ft. Sam Houston, TX 78234-6102, 
Telephone: (210) 295-1271, Fax: (210) 295-2789. E-mail Address: 
<a href="/cdn-cgi/l/email-protection#51133021233420243422252211253c307f3e22357f3c383d"><span class="__cf_email__" data-cfemail="084a69787a6d797d6d7b7c7b487c656926677b6c26656164">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee regarding the Uniform 
Formulary.
    Meeting Agenda:
    1. Sign-In.
    2. Welcome and Opening Remarks.
    3. Public Citizen Comments.
    4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item).
    a. Pancreatic Enzymes.
    b. Inflammatory Bowel Syndrome (IBS)/Inflammatory Bowel Disease 
(IBD).
    c. Antilipidemics--Lip-2.
    d. Designated Newly Approved Drugs in Already-Reviewed Classes.
    e. Pertinent Utilization Management Issues.
    f. Drugs Recommended for Non-Formulary Placement Due to Non-
Compliance with the National Defense Authorization Act for Fiscal Year 
2008, Section 703.
    5. Panel Discussions and Vote.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
Title 41, Code of Federal Regulations (CFR), Section 102-3.140 through 
102-3.165, and the availability of space this meeting is open to the 
public. Seating is limited and will be provided only to the first 220 
people signing-in. All persons must sign-in legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 7:30 a.m. to 9 a.m. to 
discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue, NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer (DFO). The DFO's contact 
information can be obtained from the General Services Administration's 
Federal Advisory Committee Act Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than five business days 
prior to the meeting in question. The DFO will review all submitted 
written statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside one hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting, for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than five minutes to present 
their comments, and at the end of the one hour time period, no further 
public comments will be accepted. Anyone who signs up to address the 
Panel, but is unable to do so due to the time limitation, may submit 
their comments in writing; however, they must

[[Page 11213]]

understand that their written comments may not be reviewed prior to the 
Panel's deliberation. Accordingly, the Panel recommends that 
individuals and interested groups consider submitting written 
statements instead of addressing the Panel.

    Dated: February 23, 2011.
Morgan F. Park,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2011-4436 Filed 2-28-11; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>